1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2.Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine. 2017;39:101042831771462.
3.Sugimoto M, Yamaoka Y, Furuta T. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World Journal of Gastroenterology. 2010;16:1188–200.
4.Cong AW, Sun YH, Shen ZB, Wang XF, Yin YQ, Fang Y, et al. Relationship between clinicopathologic factors and prognosis of patients with early gastric cancer. Chinese Journal of Digestive Surgery. 2018:338–40.
5.Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer:Prevention,screening and early diagnosis. World Journal of Gastroenterology. 2014;20:13842.
6.Lizbeth RK, Augustine D, Rao RS, Sowmya SV, Patil S. Biomarkers in Tumorigenesis Using Cancer Cell Lines: A Systematic Review. Asian Pacific Journal of Cancer Prevention Apjcp. 2017;18:2329–37.
7.Nagaraj SH, Reverter A. A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer. BMC Syst Biol. 2011;5:35.
8.Tetsuya U, Stefano V, Hiroshi O, Masayoshi S, Cristian T, Simona R, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncology. 2010;11:136–46.
9.Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, et al. Lack of microRNA–101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012;228:31–44.
10.Dong X, Liu Y. Expression and significance of miR–24 and miR–101 in patients with advanced gastric cancer. Oncol Lett. 2018;16:5769–74.
11.Rossi T, Tedaldi G, Petracci E, Abou Khouzam R, Ranzani GN, Morgagni P, et al. E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer. Int J Mol Sci. 2019;20.
12.Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, et al. Low plasma levels of miR–101 are associated with tumor progression in gastric cancer. Oncotarget. 2017;8:106538–50.
13.Zhang Y, Han T, Feng D, Li J, Wu M, Peng X, et al. Screening of non-invasive miRNA biomarker candidates for metastasis of gastric cancer by small RNA sequencing of plasma exosomes. Carcinogenesis. 2019.
14.Zoalfaghari A, Aletaha N, Roushan N, Taslimi R, Foroutan H, Faridnia B. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population. Medical Journal of the Islamic Republic of Iran. 2014;28:150-.
15.Xin L, Tang JH, Shen GR, Hao S, Yang HL. The value of PG Ⅰ,PG Ⅱ in diagnosis of atrophic gastritis and early gastric cancer. Clinical Journal of Medical Officers. 2012.
16.Zhang XM, Li JX, Zhang GY, Li XH, Gu H. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China. BMC Gastroenterol. 2014;14:3.
17.Liu WJ, Xu Q, Sun LP, Dong QG, He CY, Yuan Y. Expression of serum let–7c, let–7i, and let–7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease. Tumour Biol. 2015;36:3337–43.
18.Wu YF, Xu Q, He CY, Li Y, Liu JW, Deng N, et al. Association of Polymorphisms in three pri-miRNAs that Target Pepsinogen C with the Risk and Prognosis of Gastric Cancer. Sci Rep. 2017;7:39528.
19.Livak KJ ST. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T))Method. METHODS. 2001;Dec;25(4):402–8.
20.Walker R, Poleszczuk J, Mejia J, Lee JK, Coppola D. Toward early detection of Helicobacter pylori-associated gastric cancer. Gastric Cancer Official Journal of the International Gastric Cancer Association & the Japanese Gastric Cancer Association. 2017;21:1–8.
21.Tan YK, Fielding JWL. Early diagnosis of early gastric cancer. European Journal of Gastroenterology & Hepatology.18:821–9.
22.Wu WKK, Lee CW, Cho CH, Fan D, Wu K, Yu J, et al. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 2010;29:5761–71.
23.Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA–125a–5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011;17:2725–33.
24.Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R. Clinicopathological and prognostic significance of microRNA–107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep. 2012;27:1759–64.
25.Naito Y, Yasuno K, Tagawa H, Sakamoto N, Oue N, Yashiro M, et al. MicroRNA–145 is a potential prognostic factor of scirrhous type gastric cancer. Oncol Rep. 2014;32:1720–6.
26.Zhao J, Zhu C, Li Z. Diagnostic value of serum pepsinogen, gastrin–17 and helicobacter pylori antibody for atrophic gastritis and gastric cancer. Chinese Journal of Gastroenterology. 2016.
27.Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–53.
28.Begum A, Baten MA, Begum Z, Ahsan MM, Rahman SF, Chowdhury F, et al. Role of Serum Pepsinogen I and II Ratio in Screening of Gastric Carcinoma. Mymensingh Medical Journal Mmj. 2017;26:628.
29.Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. 2005;54:764–8.
30.Sembiring J, Sarumpaet K, Ganie RA. Diagnostic test pepsinogen I and combination with tumor marker CEA in gastric cancer. Iop Conference Series: Earth & Environmental Science; 2018.
31.Niu WW, Yang CC, Duan ZY, Huo XH, Gastroenterology DO. The diagnostic value of miRNA–92a combined with micro pepsinogen in gastric carcinoma. Journal of Hebei Medical University. 2017.
32.Wu G, Chen L, Zhao C, Xiao M. The value of combined detection of serum gastrin–17 and pepsinogen in the early screening of gastric cancer. Biomedical Research-tokyo. 2017;28:7972–6.